Form 4: Candel Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Charles Schoch, Interim CFO of Candel Therapeutics, sold 9,971 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On January 8, 2025, Charles Schoch, the Interim Chief Financial Officer of Candel Therapeutics, sold 9,971 shares of the company's common stock.
- The shares were sold at a price of $8.2182 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units, as required by the company's mandatory sell-to-cover policy.
- Following the transaction, Schoch directly owns 52,549 shares of Candel Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and employees. These transactions are typically disclosed through Form 4 filings with the SEC.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of transaction: Charles Schoch sold 9,971 shares of Candel Therapeutics common stock. |
| 01/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.